AstraZeneca (AZN), Acerta Announce Prelim. Acalabrutinib Phase 1/2 Data in CLL; Median PFS Not Yet Met
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) and its hematology Center of Excellence, Acerta Pharma, announced preliminary results from the Phase I/II ACE-CL-001 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
